These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1322 related articles for article (PubMed ID: 7693990)

  • 1. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
    Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognosis in pT3b infiltrating tumors of the bladder treated by adjuvant chemotherapy].
    Sahwi A; Robert M; Delbos O; Legouffe E; Guiter J; Navratil H
    Prog Urol; 1998 Dec; 8(6):1007-11. PubMed ID: 9894259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
    J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M; Kotake T
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adjuvant chemotherapy following total cystectomy for invasive bladder cancer with bleomycin, vincristine and methotrexate].
    Takeuchi S; Yamada T; Sekine H; Katoh M; Washizuka M; Fukui I; Yokokawa M
    Hinyokika Kiyo; 1984 Nov; 30(11):1619-25. PubMed ID: 6084949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
    Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N; Arima K; Sugimura Y
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination chemotherapy with methotrexate, vincristine, cis-platinum, cyclophosphamide, adriamycin, and bleomycin: MVP-CAB for disseminated urological cancer].
    Fujii A; Morishita S; Nakamura I; Oka Y; Ohshima H; Nagata H; Iwamoto T; Itoh N; Nakagawa Y; Miyazaki S
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):55-62. PubMed ID: 1691254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A study of the use of methotrexate, vincristine, cis-platinum, cyclophosphamide, adriamycin, bleomycin (MVP-CAB) in metastatic transitional cell carcinoma].
    Fujii A; Den S; Nakamura I; Ohshima H; Nagata H; Izumi T; Takechi Y; Kawaida T; Kamidono S; Yasuno H
    Hinyokika Kiyo; 1987 May; 33(5):697-703. PubMed ID: 2444083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
    Rassweiler J; Rüther U; Bäuerle K; Bub P; Jipp P; Eisenberger F
    Urologe A; 1989 Jan; 28(1):25-30. PubMed ID: 2922897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy.
    Park J; Park S; Song C; Doo C; Cho YM; Ahn H; Kim CS
    Urology; 2007 Aug; 70(2):257-62. PubMed ID: 17826485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adjuvant chemotherapy with MVP-CAB (methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin and bleomycin) for epithelial tumors of the upper urinary tract].
    Fujii A; Oka N; Murata Y; Higuchi A; Itoh N; Ishikawa J; Tanaka H
    Nihon Hinyokika Gakkai Zasshi; 1992 Oct; 83(10):1609-14. PubMed ID: 1279258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [M-VAC chemotherapy for patients with lymph node metastases and/or locally advanced bladder carcinoma].
    Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Nakatsu H; Kume T; Kodama M; Masu C
    Hinyokika Kiyo; 1989 Aug; 35(8):1323-7. PubMed ID: 2683648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
    Lehmann J; Retz M; Wiemers C; Beck J; Thüroff J; Weining C; Albers P; Frohneberg D; Becker T; Funke PJ; Walz P; Langbein S; Reiher F; Schiller M; Miller K; Roth S; Kälble T; Sternberg D; Wellek S; Stöckle M;
    J Clin Oncol; 2005 Aug; 23(22):4963-74. PubMed ID: 15939920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.